Technical
Channels

Drug Discovery

Drug Development

Drug Manufacturing

Drug Delivery

Clinical Trials

Regulatory and Legal

Alliances and Mergers

QA/QC and Compliance

Pharmaceutical Processing and Packaging

Change text size [+] [-]

Qiagen and WuXi AppTec Partner for Biomarker Development in China

Wednesday, January 13, 2010
 Email This |  Printer Friendly

Qiagen Asia Pacific and WuXi AppTec have announced a partnership to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases.

The former will provide a complete portfolio of instrumentation, training, and consumables and the latter will provide laboratory facilities and staff to execute the services. The laboratory is located at the latter's campus in Shanghai and will begin operating immediately.

Under the terms of the partnership agreement, both companies will also work to develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that Qiagen intends to bring to market.


Share this:   Del.icio.us | 
Digital Edition



Singapore's Preclinical R&D industry should differentiate itself in Asia by competing on quality rather than on price.
Yes
No
View results


ABOUT PHARMA ASIA | FREE SUBSCRIPTION | CONTACT US

© 2010 Ten Alps Communications Asia. All rights reserved.
Use of this Web site is subjected to its Terms and Conditions of Use. View our Privacy Policy